SI9200406A - Bradykinin antagonists for treatment of acute pancreatitis - Google Patents
Bradykinin antagonists for treatment of acute pancreatitis Download PDFInfo
- Publication number
- SI9200406A SI9200406A SI19929200406A SI9200406A SI9200406A SI 9200406 A SI9200406 A SI 9200406A SI 19929200406 A SI19929200406 A SI 19929200406A SI 9200406 A SI9200406 A SI 9200406A SI 9200406 A SI9200406 A SI 9200406A
- Authority
- SI
- Slovenia
- Prior art keywords
- arg
- pro
- stands
- gly
- hyp
- Prior art date
Links
- 206010033645 Pancreatitis Diseases 0.000 title claims abstract description 18
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 206010033647 Pancreatitis acute Diseases 0.000 title claims abstract description 14
- 201000003229 acute pancreatitis Diseases 0.000 title claims abstract description 14
- 239000003152 bradykinin antagonist Substances 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- FXHCFPUEIDRTMR-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;chloride Chemical compound Cl.C1=CC=C2CNC(C(=O)O)CC2=C1 FXHCFPUEIDRTMR-UHFFFAOYSA-N 0.000 claims abstract description 14
- -1 mercapto, hydroxyphenyl Chemical group 0.000 claims abstract description 13
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims abstract description 7
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims abstract description 4
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical group NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 4
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- RNFSRGBKGWQTPO-SKXRKSCCSA-N icatibant Chemical compound NC(=N)NCCC[C@@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C[C@@H](O)C1 RNFSRGBKGWQTPO-SKXRKSCCSA-N 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract description 2
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 238000001802 infusion Methods 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 14
- 101800004538 Bradykinin Proteins 0.000 description 13
- 102400000967 Bradykinin Human genes 0.000 description 13
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 13
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 108010010737 Ceruletide Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 108010091748 peptide A Proteins 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 239000004382 Amylase Substances 0.000 description 7
- 102000013142 Amylases Human genes 0.000 description 7
- 108010065511 Amylases Proteins 0.000 description 7
- 102000001399 Kallikrein Human genes 0.000 description 7
- 108060005987 Kallikrein Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 235000019418 amylase Nutrition 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000004882 Lipase Human genes 0.000 description 6
- 108090001060 Lipase Proteins 0.000 description 6
- 239000004367 Lipase Substances 0.000 description 6
- 108010060035 arginylproline Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019421 lipase Nutrition 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960003699 evans blue Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 108010050297 hydroxyprolyl-glycine Proteins 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- WFDSWNXTPKLLOT-UHNVWZDZSA-N 2-[[(2s,4r)-4-hydroxypyrrolidin-1-ium-2-carbonyl]amino]acetate Chemical compound O[C@H]1CN[C@H](C(=O)NCC(O)=O)C1 WFDSWNXTPKLLOT-UHNVWZDZSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 241000157855 Cinchona Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- COXVTLYNGOIATD-UHFFFAOYSA-N Evans blue free acid Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C(N)C2=C(O)C(N=NC3=CC=C(C=C3C)C=3C=C(C(=CC=3)N=NC=3C(=C4C(N)=C(C=C(C4=CC=3)S(O)(=O)=O)S(O)(=O)=O)O)C)=CC=C21 COXVTLYNGOIATD-UHFFFAOYSA-N 0.000 description 1
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229930190815 caerulein Natural products 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001706 ceruletide Drugs 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000003410 quininyl group Chemical group 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP91122055 | 1991-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI9200406A true SI9200406A (en) | 1993-06-30 |
Family
ID=8207466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI19929200406A SI9200406A (en) | 1991-12-21 | 1992-12-21 | Bradykinin antagonists for treatment of acute pancreatitis |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US5670619A (es) |
| EP (1) | EP0548825B1 (es) |
| JP (1) | JP3588472B2 (es) |
| KR (1) | KR930012034A (es) |
| CN (1) | CN1073603A (es) |
| AT (1) | ATE152733T1 (es) |
| AU (1) | AU662188B2 (es) |
| BG (1) | BG97168A (es) |
| BR (1) | BR9205062A (es) |
| CA (1) | CA2085781C (es) |
| CY (1) | CY2116B1 (es) |
| CZ (1) | CZ375692A3 (es) |
| DE (1) | DE69219574T2 (es) |
| DK (1) | DK0548825T3 (es) |
| ES (1) | ES2101017T3 (es) |
| FI (1) | FI925782A (es) |
| GR (1) | GR3024179T3 (es) |
| HU (1) | HU214056B (es) |
| IL (1) | IL104163A0 (es) |
| MA (1) | MA22743A1 (es) |
| MX (1) | MX9207440A (es) |
| NO (1) | NO924925L (es) |
| PL (1) | PL297044A1 (es) |
| SI (1) | SI9200406A (es) |
| TW (1) | TW199863B (es) |
| YU (1) | YU108192A (es) |
| ZA (1) | ZA929829B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105172B1 (en) | 1999-11-18 | 2006-09-12 | Bolla John D | Treatment of rosacea |
| US20040248809A1 (en) * | 2003-02-07 | 2004-12-09 | Aventis Pharma Deutschland Gmbh | Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis |
| RU2425669C1 (ru) * | 2010-04-13 | 2011-08-10 | Общество С Ограниченной Ответственностью "Гамаветфарм" | Средство для профилактики и лечения острого и хронического панкреатита |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2964956D1 (en) * | 1978-07-18 | 1983-04-07 | Kabi Ab | Bradykinin inhibiting tripeptide derivatives, process for their preparation and pharmaceutical preparations containing them |
| US4801613A (en) * | 1985-06-13 | 1989-01-31 | Nova Technology Limited Partnership | Bradykinin antagonist peptides |
| US4693993A (en) * | 1985-06-13 | 1987-09-15 | Stewart John M | Bradykinin antagonist peptides |
| US4923963A (en) * | 1987-09-02 | 1990-05-08 | Nova Technology Limited Partnership | Bradykinin antagonist peptides |
| US5162497A (en) * | 1987-09-24 | 1992-11-10 | The Administrators Of The Tulane Educational Fund | Bradykinin analogs with non-peptide bond |
| DE4013270A1 (de) * | 1990-04-26 | 1991-10-31 | Hoechst Ag | Peptide mit bradykinin-antagonistischer wirkung |
| IE63490B1 (en) * | 1988-11-24 | 1995-05-03 | Hoechst Ag | Peptides having bradykinin antagonist action |
| DE3926822A1 (de) * | 1989-08-14 | 1991-02-21 | Hoechst Ag | Peptide mit bradykinin-antagonistischer wirkung |
| WO1991009055A1 (en) * | 1989-12-08 | 1991-06-27 | Boston University | Acylated bradykinin antagonists and uses therefor |
| EP0451791A2 (de) * | 1990-04-12 | 1991-10-16 | Hoechst Aktiengesellschaft | Langwirksame Liposomenpräparate von Peptidarzneistoffen und Verfahren zu ihrer Herstellung |
-
1992
- 1992-03-26 TW TW081102310A patent/TW199863B/zh active
- 1992-12-14 BG BG097168A patent/BG97168A/bg unknown
- 1992-12-16 MA MA23033A patent/MA22743A1/fr unknown
- 1992-12-17 AU AU30212/92A patent/AU662188B2/en not_active Ceased
- 1992-12-17 PL PL29704492A patent/PL297044A1/xx unknown
- 1992-12-18 ES ES92121558T patent/ES2101017T3/es not_active Expired - Lifetime
- 1992-12-18 NO NO92924925A patent/NO924925L/no unknown
- 1992-12-18 DE DE69219574T patent/DE69219574T2/de not_active Expired - Lifetime
- 1992-12-18 YU YU108192A patent/YU108192A/sh unknown
- 1992-12-18 CZ CS923756A patent/CZ375692A3/cs unknown
- 1992-12-18 BR BR9205062A patent/BR9205062A/pt not_active Application Discontinuation
- 1992-12-18 DK DK92121558.8T patent/DK0548825T3/da active
- 1992-12-18 MX MX9207440A patent/MX9207440A/es unknown
- 1992-12-18 CA CA002085781A patent/CA2085781C/en not_active Expired - Lifetime
- 1992-12-18 AT AT92121558T patent/ATE152733T1/de active
- 1992-12-18 IL IL104163A patent/IL104163A0/xx unknown
- 1992-12-18 EP EP92121558A patent/EP0548825B1/en not_active Expired - Lifetime
- 1992-12-18 JP JP33773592A patent/JP3588472B2/ja not_active Expired - Lifetime
- 1992-12-18 ZA ZA929829A patent/ZA929829B/xx unknown
- 1992-12-18 FI FI925782A patent/FI925782A/fi unknown
- 1992-12-19 KR KR1019920024742A patent/KR930012034A/ko not_active Application Discontinuation
- 1992-12-21 SI SI19929200406A patent/SI9200406A/sl unknown
- 1992-12-21 CN CN92114564A patent/CN1073603A/zh active Pending
- 1992-12-21 HU HU9204074A patent/HU214056B/hu not_active IP Right Cessation
-
1994
- 1994-04-22 US US08/232,338 patent/US5670619A/en not_active Expired - Lifetime
-
1997
- 1997-07-22 GR GR970401824T patent/GR3024179T3/el unknown
-
1998
- 1998-09-29 CY CY9800034A patent/CY2116B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI925782A (fi) | 1993-06-22 |
| HU9204074D0 (en) | 1993-04-28 |
| ZA929829B (en) | 1994-02-16 |
| CY2116B1 (en) | 2002-04-26 |
| DE69219574D1 (de) | 1997-06-12 |
| CA2085781A1 (en) | 1993-06-22 |
| CZ375692A3 (en) | 1993-12-15 |
| YU108192A (sh) | 1995-12-04 |
| AU662188B2 (en) | 1995-08-24 |
| MX9207440A (es) | 1993-07-01 |
| EP0548825A1 (en) | 1993-06-30 |
| JPH05255107A (ja) | 1993-10-05 |
| JP3588472B2 (ja) | 2004-11-10 |
| CN1073603A (zh) | 1993-06-30 |
| HU214056B (en) | 1997-12-29 |
| FI925782A0 (fi) | 1992-12-18 |
| ES2101017T3 (es) | 1997-07-01 |
| NO924925L (no) | 1993-06-22 |
| NO924925D0 (no) | 1992-12-18 |
| ATE152733T1 (de) | 1997-05-15 |
| CA2085781C (en) | 2003-09-23 |
| KR930012034A (ko) | 1993-07-20 |
| PL297044A1 (en) | 1993-09-06 |
| BR9205062A (pt) | 1993-09-28 |
| US5670619A (en) | 1997-09-23 |
| GR3024179T3 (en) | 1997-10-31 |
| TW199863B (es) | 1993-02-11 |
| DE69219574T2 (de) | 1997-11-13 |
| MA22743A1 (fr) | 1993-07-01 |
| HUT63336A (en) | 1993-08-30 |
| AU3021292A (en) | 1993-06-24 |
| IL104163A0 (en) | 1993-05-13 |
| BG97168A (bg) | 1993-12-24 |
| DK0548825T3 (da) | 1997-11-03 |
| EP0548825B1 (en) | 1997-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Celis et al. | Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone | |
| Heinz-Erian et al. | [D-Phe12] bombesin analogues: a new class of bombesin receptor antagonists | |
| US6747008B1 (en) | Methods for treating and preventing alopecia | |
| AU4364896A (en) | Use of angiotensin ii fragments and analogs thereof in tissue repair | |
| WO1992013564A1 (en) | Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor | |
| CA2776581A1 (en) | Methods for the prevention or treatment of heart failure | |
| US6821953B1 (en) | Methods for treating and preventing damage to mucosal tissue | |
| CN111920939A (zh) | 血管紧张素ii单独或以组合方式用于治疗低血压 | |
| AU5000993A (en) | Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues | |
| EP0871464B1 (en) | Bradykinin analogs as selective thrombin inhibitors | |
| Yamaguchi et al. | Plasma vasopressin response to peripheral administration of angiotensin in conscious rats | |
| Li et al. | An oviposition-inducing peptide: isolation, localization, and function of avian galanin in the quail oviduct | |
| SI9200406A (en) | Bradykinin antagonists for treatment of acute pancreatitis | |
| WO2013192238A2 (en) | Compositions and methods for treatment of diabetes | |
| Majima et al. | Poststatin, a novel inhibitor of bradykinin-degrading enzymes in rat urine | |
| EP1239867B1 (en) | Methods for treating and preventing damage to mucosal tissue | |
| EP1909814B1 (en) | Peptides for induction and enhancement of apoptosis in tumor cells | |
| Gerdin et al. | Structural requirements for microvascular permeability-increasing ability of peptides: Studies on analogues of a fibrinogen pentapeptide fragment | |
| Hata et al. | Comparison of the biological effects of two angiotensin II analogues in hypertensive patients with sodium depletion | |
| Vesterqvist et al. | Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans | |
| Rakugi et al. | Renal interaction of atrial natriuretic peptide with angiotensin II: glomerular and tubular effects | |
| US6372713B1 (en) | Anti-depressant effects of corticotropin release inhibiting factor | |
| Oluyomi et al. | Antinociceptive activity of peptides related to interleukin-1β and melanocyte stimulating hormone | |
| THER | TWICE MONTHLY BIBLIOGRAPHY ON NEUROPEPTIDES-EARLY OCTOBER PREPARED BY SHEFFIELD UNIYERSITY BIOMEDICAL INFORMATION SERVICE SHEFFIELD SlO 2TN |